These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 28668403

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA, Burger IA, Goldman DA, Miccò M, Sosa RE, Weber W, Chi DS, Hricak H, Sala E.
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [Abstract] [Full Text] [Related]

  • 3. 18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value.
    Liu S, Feng Z, Wen H, Jiang Z, Pan H, Deng Y, Zhang L, Ju X, Chen X, Wu X.
    Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
    [Abstract] [Full Text] [Related]

  • 4. Correlation of 18F-FDG uptake on PET/CT with Ki67 immunohistochemistry in pre-treatment epithelial ovarian cancer.
    Mayoral M, Paredes P, Saco A, Fusté P, Perlaza P, Tapias A, Fernandez-Martinez A, Vidal L, Ordi J, Pavia J, Martinez-Roman S, Lomeña F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Sep; 37(2):80-86. PubMed ID: 28869177
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125.
    Glickman A, Paredes P, Carreras-Diéguez N, Niñerola-Baizán A, Gaba L, Pahisa J, Fusté P, Del Pino M, Díaz-Feijóo B, González-Bosquet E, Agustí N, Sánchez-Izquierdo N, Fuster D, Perissinotti A, Romero I, Fernández-Galán E, Carrasco JL, Gil-Ibáñez B, Torné A.
    Eur Radiol; 2022 Apr; 32(4):2200-2208. PubMed ID: 34586465
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW, Oh JS, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY.
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET/CT as predictor of tumour biology and prognosis in epithelial ovarian carcinoma.
    González García B, García Vicente AM, Jiménez Londoño GA, Pena Pardo FJ, Bellón Guardia ME, Talavera Rubio MP, Palomar Muñoz A, Gómez Herrero P, Soriano Castrejón ÁM.
    Rev Esp Med Nucl Imagen Mol; 2017 Aug; 36(4):233-240. PubMed ID: 28284928
    [Abstract] [Full Text] [Related]

  • 9. Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.
    Yamamoto M, Tsujikawa T, Fujita Y, Chino Y, Kurokawa T, Kiyono Y, Okazawa H, Yoshida Y.
    Cancer Sci; 2016 Apr; 107(4):478-85. PubMed ID: 26789906
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.
    Lee M, Lee H, Cheon GJ, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    Eur Radiol; 2017 Jan; 27(1):16-23. PubMed ID: 27121932
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer.
    Mayoral M, Fernandez-Martinez A, Vidal L, Fuster D, Aya F, Pavia J, Pons F, Lomeña F, Paredes P.
    Rev Esp Med Nucl Imagen Mol; 2016 Jan; 35(2):88-95. PubMed ID: 26541072
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, Pandey AK, Sekhar Bal C, Patel CD, Sharma P, Agarwal KK, Kumar R.
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH, Cho A, Yun M, Choi YD, Rha SY, Kang WJ.
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V, Cascales-Campos PA, Gil J, Frutos L, Andrade RJ, Fuster-Quiñonero M, Feliciangeli E, Gil E, Parrilla P.
    Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.